AVAnu Valkna

Anu Valkna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anu Valkna has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    All-in-one exome sequencing approach for genetic testing of unexplained premature ovarian insufficiency

    by Anu Valkna, Triin Kikas, Ülle Jakovlev, Oliver Mõttus, Avirup Dutta, Külli Erlang, Margus Punab, Kristiina Rull, Maris Laan

    STUDY QUESTION: Is exome sequencing (ES) an efficient approach for simultaneous analysis of causative single gene defects and copy number variants (CNV) in unexplained premature ovarian insufficiency (POI)? SUMMARY ANSWER: Among 51 idiopathic POI cases, a conservative molecular diagnostic yield of 12% was achieved with equal contribution of pathogenic or likely pathogenic (P/LP) monogenic causes and pathogenic microdeletions. WHAT IS KNOWN ALREADY: POI is a clinically and genetically heterogeneous condition, yet most cases remain idiopathic. Although numerous monogenic causes and CNVs have been implicated in POI, standardized clinical guidelines for comprehensive genetic analysis are still lacking. STUDY DESIGN, SIZE, AND DURATION: This observational study of 51 unexplained POI cases implemented an all-in-one ES-based approach to analyze P and LP variants in 288 POI candidate genes and large (>0.5 Mb) pathogenic CNVs leading to POI. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were recruited and phenotyped at two tertiary care women’s health and endocrinology centers in Estonia. Bioinformatic processing of ES data and assessment of rare causal variants in POI were performed using an in-house analysis pipeline including automated filtering and manual assessment for pathogenicity, followed by experimental validation via Sanger sequencing (monogenic findings) and chromosomal microarray analysis (CNVs). MAIN RESULTS AND THE ROLE OF CHANCE: Six of 51 unexplained POI cases had confident molecular findings, including three cases with P/LP monogenic variants and three carrying large pathogenic CNVs. Overall molecular diagnostic yield was estimated to be 12% (6 of 51). There was a statistically significant overrepresentation of likely causal genetic findings in primary amenorrhea (5 of 9 cases, 56%) compared to secondary amenorrhea/oligomenorrhea (1 of 42 cases, 2%) (P=3.0 × 10−4). Primary amenorrhea cases presented diverse findings – TP63 p.(Arg97Gly) in three sisters (including one identified by cascade screening), 15q25.2 microdeletion in two unrelated subjects (POI relevant haploinsufficient genes: CPEB1, BNC1), and NR5A1 p.(Gly328Arg) in one case. A secondary amenorrhea case with ∼8.5 Mb microdeletion at Xq27.3–Xq28 enabled to narrow down a critical region for non-recurrent Xq terminal losses causing POI (relevant haploinsufficient genes FMR1, AFF2, CETN2, HAUS7, and EMD). Additionally, heterozygous variants TBX6 c.622-2A>T, EXO1 c.136del, and NR2F2 p.(Val307Ala), as well as 1q21.1 microdeletion (two carriers), 1p36.22, and 12q21.1 microduplications were classified as potentially interesting Variants of Uncertain Significance (VUS) that require validation before their causal link to isolated POI can be assigned. TBX6 c.622-2A>T and 1q21.1 del have been implicated in other primary phenotypes, Mayer–Rokitansky–Küster–Hauser syndrome (MRKH, Müllerian anomalies), and 1q21.1 microdeletion syndrome (MIM #612474), respectively. A novel variant NR2F2 p.(Val307Ala) was identified in an isolated oligomenorrhea patient; the same substitution was independently detected in an unrelated male subject presenting oligozoospermia and unilateral cryptorchidism. No autosomal recessive POI cases were identified in our cohort, supporting a high level of heterogeneity and population-specificity in the genetic etiologies of POI, likely shaped by diverse demographic histories. LARGE SCALE DATA: All variants linked identified in this study have been submitted to the NCBI ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) and FerGI (https://www.eshre.eu/Specialty-groups/Special-Interest-Groups/Reproductive-Genetics/FeRGI) databases. LIMITATIONS, REASONS FOR CAUTION: All recruited participants were of white European ancestry and living in Estonia. Thus, the results might not apply to other ethnic groups. This study was conducted in a relatively small and well-selected cohort. Validation in larger and more diverse cohorts is needed to further assess the utility of ES in solving idiopathic POI cases. WIDER IMPLICATIONS OF THE FINDINGS: The study's findings support the efficient use of ES as a comprehensive, all-in-one genetic test to achieve molecular diagnosis in unexplained POI, capturing both monogenic variants and pathogenic CNVs. Expanded genetic testing in POI is conceptually and clinically justified to reduce idiopathic cases and enable timely personalized management of reproductive and general health, including cascade testing of at-risk relatives. Given that ES enables the detection of both monogenic variants and CNVs, stepwise strategies may no longer be the most optimal, underscoring an urgent need to develop a standardized pipeline and guidelines for the generation, analysis, and interpretation of NGS data as well as for the counseling and management of patients based on their molecular findings. FUNDING: This study was funded by the Estonian Research Council grants PRG1021 and PRG3041 (to M.L.). DISCLOSURES: The authors declare no conflicts of interest.


  • Open Access

    Significantly increased load of hereditary cancer-linked germline variants in infertile men

    by Anu Valkna, Anna-Grete Juchnewitsch, Lisanna Põlluaas, Kristiina Lillepea, Stanislav Tjagur, Avirup Dutta, Kristjan Pomm, Margus Punab, Maris Laan

    STUDY QUESTION: What is the load and profile of hereditary cancer-linked germline variants in infertile compared to fertile men? SUMMARY ANSWER: This study showed almost 5-fold enrichment of disease-causing findings in hereditary cancer genes in infertile compared to fertile men (6.9% vs 1.5%, P = 2.3 × 10−4). WHAT IS KNOWN ALREADY: Epidemiological studies have revealed that men with low sperm count have a 2-fold higher risk of developing cancer during their lifetime. Our recent study observed a 4-fold increased prevalence of cancer in men with monogenic infertility compared to the general male population (8% vs 2%). Shared molecular etiologies of male infertility and cancer have been proposed. STUDY DESIGN, SIZE, DURATION: This retrospective study analyzed germline likely pathogenic and pathogenic (LP/P) variants in 157 hereditary cancer genes in 522 infertile and 323 fertile men recruited to the ESTonian ANDrology (ESTAND) cohort. PARTICIPANTS/MATERIALS, SETTING, METHODS: All study participants (n = 845) had been recruited and phenotyped at an Andrology Clinic. Identification of LP/P variants in the cancer gene panel was performed from an exome sequencing dataset generated for the study cohort. All variants passed an automated filtering process, final manual assessment of pathogenicity, and experimental confirmation using Sanger sequencing. Retrospective general health records were available for 36 out of 41 (88%) men with LP/P findings. MAIN RESULTS AND THE ROLE OF CHANCE: Infertile men presented a nearly 5-fold higher load of LP/P findings (36 of 522 cases, 6.9%) compared to fertile subjects (5 of 323, 1.5%; odds ratio (OR) = 4.7, 95% CI 1.81–15.5; P = 2.3 × 10−4) spanning over 24 hereditary cancer genes. The prevalence of findings was not significantly different between azoospermic and oligozoospermic cases. There was also no enrichment of findings in men with a history of cryptorchidism. By the time of the study, six men carrying hereditary cancer variants had been diagnosed with a tumor. Family members affected with cancer had been documented for 10 of 14 cases with available pedigree health data. Nearly half of the infertile men with LP/P findings (17 out of 36) carried variants in genes belonging to the Fanconi anemia (FA) pathway involved in the maintenance of genomic integrity in mitosis and meiosis, repair of DNA double-stranded breaks, and interstrand crosslinks. Overall, FA-pathway genes BRCA2 (monoallelic) and FANCM (biallelic) were the most frequently affected loci (five subjects per gene). LP/P findings in pleiotropic genes linked to human development and hereditary cancer (TSC1, PHOX2B, WT1, SPRED1, NF1, LZTR1, HOXB13) were identified in several patients with syndromic phenotypes. Four cryptorchid infertile men were carriers of MLH1, MSH2, and MSH6 variants implicated in Lynch syndrome. Future studies will reveal whether this observation is a by chance or replicable finding. Most hereditary cancer genes with LP/P variants show high expression in one or more testicular cell types, and mouse models for 15 of 24 affected genes have been reported to exhibit male sub- or infertility. These data support shared genetic etiology of impaired spermatogenesis and cancer. A significantly increased fraction of cancer-linked variants in infertile compared to fertile men could also explain the reported high prevalence of cancer as a comorbidity in male infertility. LARGE SCALE DATA: All hereditary cancer-linked variants identified in this study have been submitted to the National Center for Biotechnology Information (NCBI) ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/). LIMITATIONS, REASONS FOR CAUTION: All recruited participants were of white European ancestry and living in Estonia. Thus, the results might not apply to other ethnic groups. Due to the young age of study participants (median age 34.4 years), the true incidence of cancer during lifetime could not be assessed. As retrospective clinical data were not available for all men, it was not possible to evaluate all possible genotype–phenotype links. The absence of genetic data from family members precluded the assessment of the hereditary nature of the variants or their potential de novo occurrence. WIDER IMPLICATIONS OF THE FINDINGS: Infertility affects about 7–10% of men worldwide. In this study, one in 15 men with spermatogenic failure carried germline LP/P variants in hereditary cancer genes. As exome sequencing is gradually entering the molecular diagnostics setup in andrology, analyzing hereditary cancer-linked variants in the workup of infertile men will offer additional clinical benefits. Male factor infertility is typically diagnosed in men in their 30s, often before the onset of cancer or its symptoms. Early knowledge of germline predisposition to cancer enables timely screening and multidisciplinary management options, potentially improving the prognosis. The study data provide support for the shared monogenic etiologies of hereditary cancer and spermatogenic failure. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Estonian Research Council grant PRG1021 (M.L. and M.P.). The authors declare no conflicts of interest.